Trials with 'epigenetic' drugs: An update

Molecular Oncology

Volumn 6, Issue 6, 2012, Pages 657-682

  Nebbioso, Angela ^a   Carafa, Vincenzo ^a   Benedetti, Rosaria ^a   Altucci, Lucia ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Cancer; Clinical trials; Epi drugs; Epigenetics

Indexed keywords

4 PHENYLBUTYRIC ACID; AZACITIDINE; BEXAROTENE; CARBOPLATIN; COSITECAN; DOCETAXEL; ENFUVIRTIDE; FLAVOPIRIDOL; FLUDARABINE; FLUOROURACIL; FOLINATE CALCIUM; GEMTUZUMAB; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; HYDROXAMIC ACID; IDARUBICIN; ISOTRETINOIN; OXALIPLATIN; OZOGAMICIN; PACLITAXEL; PIVALOYLOXYMETHYL BUTYRATE; RALTEGRAVIR; SHORT CHAIN FATTY ACID; TAMOXIFEN; TEMOZOLOMIDE; UNINDEXED DRUG; UNTRANSLATED RNA; VALPROATE MAGNESIUM; VALPROIC ACID; VORINOSTAT;

AMYOTROPHIC LATERAL SCLEROSIS; BLADDER CANCER; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHROMATIN STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA METHYLATION; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; HUNTINGTON CHOREA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; LYMPHOMA; MELANOMA; MOLECULAR INTERACTION; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; UTERINE CERVIX CANCER;

EID: 84869874482     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.09.004     Document Type: Review

References (300)

1. Abdel Aziz M.T., El-Asmar M.F., El-Ibrashy I.N., Rezq A.M., Al-Malki A.L., Wassef M.A., Fouad H.H., Ahmed H.H., Taha F.M., Hassouna A.A., Morsi H.M. Effect of novel water soluble curcumin derivative on experimental type-1 diabetes mellitus (short term study). Diabetology & Metabolic Syndrome 2012, 4:30.
2. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Research 2004, 24:2783-2840.
3. Al-Salihi M., Yu M., Burnett D.M., Alexander A., Samlowski W.E., Fitzpatrick F.A. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics 2011, 6:1021-1028.
4. Alcain F.J., Villalba J.M. Sirtuin inhibitors. Expert Opinion on Therapeutic Patents 2009, 19:283-294.
5. Alcazar O., Achberger S., Aldrich W., Hu Z., Negrotto S., Saunthararajah Y., Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. International Journal of Cancer 2012, 131:18-29.
6. Amato R.J., Stephenson J., Hotte S., Nemunaitis J., Belanger K., Reid G., Martell R.E. MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma. Cancer Investigation 2012, 30:415-421.
7. Amatori S., Bagaloni I., Donati B., Fanelli M. DNA demethylating antineoplastic strategies: a comparative point of view. Genes & Cancer 2010, 1:197-209.
8. Arce C., Perez-Plasencia C., Gonzalez-Fierro A., de la Cruz-Hernandez E., Revilla-Vazquez A., Chavez-Blanco A., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Bargallo E., et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006, 1:e98.
9. Archin N.M., Cheema M., Parker D., Wiegand A., Bosch R.J., Coffin J.M., Eron J., Cohen M., Margolis D.M. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010, 5:e9390.
10. Arts J., King P., Marien A., Floren W., Belien A., Janssen L., Pilatte I., Roux B., Decrane L., Gilissen R., et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clinical Cancer Research 2009, 15:6841-6851.
11. Ashraf N., Zino S., Macintyre A., Kingsmore D., Payne A.P., George W.D., Shiels P.G. Altered sirtuin expression is associated with node-positive breast cancer. British Journal of Cancer 2006, 95:1056-1061.
12. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., Harris C., Zwiebel J., Wright J.J., Espinoza-Delgado I., et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research 2009, 15:5250-5257.
13. Balasubramanyam K., Swaminathan V., Ranganathan A., Kundu T.K. Small molecule modulators of histone acetyltransferase p300. The Journal of Biological Chemistry 2003, 278:19134-19140.
14. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., Kundu T.K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. The Journal of Biological Chemistry 2004, 279:33716-33726.
15. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. The Journal of Biological Chemistry 2004, 279:51163-51171.
16. Baliga M.S., Joseph N., Venkataranganna M.V., Saxena A., Ponemone V., Fayad R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food & Function 2012, 3. http://dx.doi.org/10.1039/C2FO30097D.
17. Banerji U., van Doorn L., Papadatos-Pastos D., Kristeleit R., Debnam P., Tall M., Stewart A., Raynaud F., Garrett M.D., Toal M., et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clinical Cancer Research 2012, 18:2687-2694.
18. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Research 2011, 21:381-395.
19. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
20. Baud M.G., Leiser T., Haus P., Samlal S., Wong A.C., Wood R.J., Petrucci V., Gunaratnam M., Hughes S.M., Buluwela L., et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. Journal of Medicinal Chemistry 2012, 55:1731-1750.
21. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
22. Binion D.G., Otterson M.F., Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008, 57:1509-1517.
23. Blackwell L., Norris J., Suto C.M., Janzen W.P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sciences 2008, 82:1050-1058.
24. Blum K.A., Advani A., Fernandez L., Van Der Jagt R., Brandwein J., Kambhampati S., Kassis J., Davis M., Bonfils C., Dubay M., et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. British Journal of Haematology 2009, 147:507-514.
25. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006, 5:769-784.
26. Borbone E., Berlingieri M.T., De Bellis F., Nebbioso A., Chiappetta G., Mai A., Altucci L., Fusco A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010, 29:105-116.
27. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. The Journal of Biological Chemistry 2005, 280:17187-17195.
28. Bosch-Presegue L., Vaquero A. The dual role of sirtuins in cancer. Genes & Cancer 2011, 2:648-662.
29. Bouzar A.B., Boxus M., Defoiche J., Berchem G., Macallan D., Pettengell R., Willis F., Burny A., Lagneaux L., Bron D., et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. British Journal of Haematology 2009, 144:41-52.
30. Bracker T.U., Sommer A., Fichtner I., Faus H., Haendler B., Hess-Stumpp H. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. International Journal of Oncology 2009, 35:909-920.
31. Bratland A., Dueland S., Hollywood D., Flatmark K., Ree A.H. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiation Oncology 2011, 6:33.
32. Braun J., Boittiaux I., Tilborg A., Lambert D., Wouters J. The dicyclo-hexyl-amine salt of RG108 (N-phthalyl-l-tryptophan), a potential epigenetic modulator. Acta Crystallographica Section E, Structure Reports Online 2010, 66:o3175-3176.
33. Brooks C.L., Gu W. How does SIRT1 affect metabolism, senescence and cancer?. Nature Reviews Cancer 2009, 9:123-128.
34. Brueckner B., Garcia Boy R., Siedlecki P., Musch T., Kliem H.C., Zielenkiewicz P., Suhai S., Wiessler M., Lyko F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Research 2005, 65:6305-6311.
35. Buglio D., Mamidipudi V., Khaskhely N.M., Brady H., Heise C., Besterman J., Martell R.E., MacBeth K., Younes A. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. British Journal of Haematology 2010, 151:387-396.
36. Burgess A., Ruefli A., Beamish H., Warrener R., Saunders N., Johnstone R., Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23:6693-6701.
37. Butler K.V., Kozikowski A.P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Current Pharmaceutical Design 2008, 14:505-528.
38. Butler L.M., Webb Y., Agus D.B., Higgins B., Tolentino T.R., Kutko M.C., LaQuaglia M.P., Drobnjak M., Cordon-Cardo C., Scher H.I., et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clinical Cancer Research 2001, 7:962-970.
39. Candelaria M., Cetina L., Perez-Cardenas E., de la Cruz-Hernandez E., Gonzalez-Fierro A., Trejo-Becerril C., Taja-Chayeb L., Chanona J., Arias D., Duenas-Gonzalez A. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. European Journal of Gynaecological Oncology 2010, 31:386-391.
40. Candelaria M., Gallardo-Rincon D., Arce C., Cetina L., Aguilar-Ponce J.L., Arrieta O., Gonzalez-Fierro A., Chavez-Blanco A., de la Cruz-Hernandez E., Camargo M.F., et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Annals of Oncology 2007, 18:1529-1538.
41. Candelaria M., Herrera A., Labardini J., Gonzalez-Fierro A., Trejo-Becerril C., Taja-Chayeb L., Perez-Cardenas E., de la Cruz-Hernandez E., Arias-Bofill D., Vidal S., et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Annals of Hematology 2011, 90:379-387.
42. Carafa V., Nebbioso A., Altucci L. Sirtuins and disease: the road ahead. Frontiers in Pharmacology 2012, 3:4.
43. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters 2008, 269:7-17.
44. Cashen A., Juckett M., Jumonville A., Litzow M., Flynn P.J., Eckardt J., LaPlant B., Laumann K., Erlichman C., DiPersio J. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Annals of Hematology 2012, 91:33-38.
45. Cebrat M., Kim C.M., Thompson P.R., Daugherty M., Cole P.A. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorganic & Medicinal Chemistry 2003, 11:3307-3313.
46. Chaib H., Prebet T., Vey N., Collette Y. Histone methyltransferases: a new class of therapeutic targets in cancer treatment?. Medecine Sciences 2011, 27:725-732.
47. Chen W.F., Huang F., Zha J. The comparison of short-term efficacies between decitabine and HA regimen for MDS/AML patients. Zhonghua Xue Ye Xue Za Zhi 2012, 33:143-144.
48. Chestnut B.A., Chang Q., Price A., Lesuisse C., Wong M., Martin L.J. Epigenetic regulation of motor neuron cell death through DNA methylation. The Journal of Neuroscience 2011, 31:16619-16636.
49. Chin S.P., Dickinson J.L., Holloway A.F. Epigenetic regulation of prostate cancer. Clinical Epigenetics 2011, 2:151-169.
50. Choo K.B. Epigenetics in disease and cancer. The Malaysian Journal of Pathology 2011, 33:61-70.
51. Coiffier B., Pro B., Prince H.M., Foss F., Sokol L., Greenwood M., Caballero D., Borchmann P., Morschhauser F., Wilhelm M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology 2012, 30:631-636.
52. Copeland R.A., Solomon M.E., Richon V.M. Protein methyltransferases as a target class for drug discovery. Nature Reviews Drug Discovery 2009, 8:724-732.
53. Crisanti M.C., Wallace A.F., Kapoor V., Vandermeers F., Dowling M.L., Pereira L.P., Coleman K., Campling B.G., Fridlender Z.G., Kao G.D., Albelda S.M. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Molecular Cancer Therapeutics 2009, 8:2221-2231.
54. Cudkowicz M.E., Andres P.L., Macdonald S.A., Bedlack R.S., Choudry R., Brown R.H., Zhang H., Schoenfeld D.A., Shefner J., Matson S., et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis 2009, 10:99-106.
55. Dandawate P.R., Vyas A., Ahmad A., Banerjee S., Deshpande J., Swamy K.V., Jamadar A., Dumhe-Klaire A.C., Padhye S., Sarkar F.H. Inclusion complex of novel curcumin analogue CDF and beta-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharmaceutical Research 2012, 29:1775-1786.
56. Darkin-Rattray S.J., Gurnett A.M., Myers R.W., Dulski P.M., Crumley T.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13143-13147.
57. Darvesh A.S., Carroll R.T., Bishayee A., Novotny N.A., Geldenhuys W.J., Van der Schyf C.J. Curcumin and neurodegenerative diseases: a perspective. Expert Opinion on Investigational Drugs 2012, 21:1123-1140.
58. Das P.M., Singal R. DNA methylation and cancer. Journal of Clinical Oncology 2004, 22:4632-4642.
59. Datta J., Ghoshal K., Denny W.A., Gamage S.A., Brooke D.G., Phiasivongsa P., Redkar S., Jacob S.T. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Research 2009, 69:4277-4285.
60. Daud A.I., Dawson J., DeConti R.C., Bicaku E., Marchion D., Bastien S., Hausheer F.A., Lush R., Neuger A., Sullivan D.M., Munster P.N. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clinical Cancer Research 2009, 15:2479-2487.
61. Davis A.J., Gelmon K.A., Siu L.L., Moore M.J., Britten C.D., Mistry N., Klamut H., D'Aloisio S., MacLean M., Wainman N., et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Investigational New Drugs 2003, 21:85-97.
62. Deng C.X. SIRT1, is it a tumor promoter or tumor suppressor?. International Journal of Biological Sciences 2009, 5:147-152.
63. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Nervi C., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295:1079-1082.
64. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Molecular Cancer Research 2007, 5:981-989.
65. Dong S.W., Cui Y.T., Zhong R.R., Liang D.C., Liu Y.M., Wang Y.G., He Z., Wang S., Liang S.J., Zhang P. Decreased expression of retinoblastoma protein-interacting zinc-finger gene 1 in human esophageal squamous cell cancer by DNA methylation. Clinical Laboratory 2012, 58:41-51.
66. Dowdell K.C., Pesnicak L., Hoffmann V., Steadman K., Remaley A.T., Cohen J.I., Straus S.E., Rao V.K. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Experimental Hematology 2009, 37:487-494.
67. Dummer R., Beyer M., Hymes K., Epping M.T., Bernards R., Steinhoff M., Sterry W., Kerl H., Heath K., Ahern J.D., et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia & Lymphoma 2012, 53:1501-1508.
68. Duvic M., Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs 2007, 16:1111-1120.
69. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
70. Eglen R.M., Reisine T. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview. Journal of Biomolecular Screening 2011, 16:1137-1152.
71. El-Khoury V., Moussay E., Janji B., Palissot V., Aouali N., Brons N.H., Van Moer K., Pierson S., Van Dyck E., Berchem G. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Molecular Cancer Therapeutics 2010, 9:1349-1360.
72. Ellis L., Pan Y., Smyth G.K., George D.J., McCormack C., Williams-Truax R., Mita M., Beck J., Burris H., Ryan G., et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research 2008, 14:4500-4510.
73. Estiu G., Greenberg E., Harrison C.B., Kwiatkowski N.P., Mazitschek R., Bradner J.E., Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. Journal of Medicinal Chemistry 2008, 51:2898-2906.
74. Fakih M.G., Groman A., McMahon J., Wilding G., Muindi J.R. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemotherapy and Pharmacology 2012, 69:743-751.
75. Fandy T.E. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Current Medicinal Chemistry 2009, 16:2075-2085.
76. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., Yang A.S., Aucott T., Dauses T., Odchimar-Reissig R., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
77. Fang M., Chen D., Yang C.S. Dietary polyphenols may affect DNA methylation. The Journal of Nutrition 2007, 137:223S-228S.
78. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nature Reviews Genetics 2006, 7:21-33.
79. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nature Reviews Cancer 2004, 4:143-153.
80. Feng R., Oton A., Mapara M.Y., Anderson G., Belani C., Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. British Journal of Haematology 2007, 139:385-397.
81. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., Ustun C., Rao R., Fernandez P., Chen J., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
82. Fonseca A.L., Kugelberg J., Starker L.F., Scholl U., Choi M., Hellman P., Akerstrom G., Westin G., Lifton R.P., Bjorklund P., Carling T. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes, Chromosomes & Cancer 2012, 51(10):949-960.
83. Force J., Rajan A., Dombi E., Steinberg S.M., Giaccone G. Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. Journal of Thoracic Oncology 2011, 6:1267-1273.
84. Forneris F., Binda C., Vanoni M.A., Battaglioli E., Mattevi A. Human histone demethylase LSD1 reads the histone code. The Journal of Biological Chemistry 2005, 280:41360-41365.
85. Foulks J.M., Parnell K.M., Nix R.N., Chau S., Swierczek K., Saunders M., Wright K., Hendrickson T.F., Ho K.K., McCullar M.V., Kanner S.B. Epigenetic drug discovery: targeting DNA methyltransferases. Journal of Biomolecular Screening 2012, 17:2-17.
86. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., Liu J., Lu A.H., Zhou N.Z., Robert M.F., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics 2008, 7:759-768.
87. Friday B.B., Anderson S.K., Buckner J., Yu C., Giannini C., Geoffroy F., Schwerkoske J., Mazurczak M., Gross H., Pajon E., et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-oncology 2012, 14:215-221.
88. Fukutomi A., Hatake K., Matsui K., Sakajiri S., Hirashima T., Tanii H., Kobayashi K., Yamamoto N. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Investigational New Drugs 2012, 30:1096-1106.
89. Fulda S., Debatin K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004, 23:6702-6711.
90. Galli M., Salmoiraghi S., Golay J., Gozzini A., Crippa C., Pescosta N., Rambaldi A. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology 2010, 89:185-190.
91. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15:875-890.
92. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. American Journal of Hematology 2012, 87:692-701.
93. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., Newsome W.M., Miller W.H., Rousseau C., Kalita A., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
94. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
95. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry 2005, 280:556-563.
96. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
97. Ghoneum M., Gollapudi S. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro. Neoplasma 2011, 58:118-123.
98. Gillenwater A.M., Zhong M., Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Molecular Cancer Therapeutics 2007, 6:2967-2975.
99. Gimsing P., Hansen M., Knudsen L.M., Knoblauch P., Christensen I.J., Ooi C.E., Buhl-Jensen P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology 2008, 81:170-176.
100. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
101. Goffin J., Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Annals of Oncology 2002, 13:1699-1716.
102. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., Tidwell M.L., Greer J., Chung E.J., Lee M.J., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109:2781-2790.
103. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annual Review of Biochemistry 2005, 74:481-514.
104. Gore L., Rothenberg M.L., O'Bryant C.L., Schultz M.K., Sandler A.B., Coffin D., McCoy C., Schott A., Scholz C., Eckhardt S.G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clinical Cancer Research 2008, 14:4517-4525.
105. Gravina G.L., Marampon F., Piccolella M., Motta M., Ventura L., Pomante R., Popov V.M., Zani B.M., Pestell R.G., Tombolini V., et al. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology 2011, 152:4550-4561.
106. Gray J., Cubitt C.L., Zhang S., Chiappori A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biology & Therapy 2012, 13:614-622.
107. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nature Reviews Genetics 2012, 13:343-357.
108. Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nature Chemical Biology 2005, 1:143-145.
109. Gu B., Ding Q., Xia G., Fang Z. EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression. Oncology Reports 2009, 21:635-640.
110. Guo L.D., Chen X.J., Hu Y.H., Yu Z.J., Wang D., Liu J.Z. Curcumin inhibits proliferation and induces apoptosis of human colorectal cancer cells by activating the mitochondria apoptotic pathway. Phytotherapy Research 2012, 26. http://dx.doi.org/10.1002/ptr.4731.
111. Gupta S.C., Kannappan R., Reuter S., Kim J.H., Aggarwal B.B. Chemosensitization of tumors by resveratrol. Annals of the New York Academy of Sciences 2011, 1215:150-160.
112. Guz J., Foksinski M., Olinski R. Global DNA hipomethylation - the meaning in carcinogenesis. Postepy Biochemii 2010, 56:16-21.
113. Hagemann S., Heil O., Lyko F., Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 2011, 6:e17388.
114. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4389-4394.
115. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. The New England Journal of Medicine 2002, 347:1593-1603.
116. Harfe B.D. MicroRNAs in vertebrate development. Current Opinion in Genetics & Development 2005, 15:410-415.
117. Hatziapostolou M., Iliopoulos D. Epigenetic aberrations during oncogenesis. Cellular and Molecular Life Sciences 2011, 68:1681-1702.
118. Hogarth P., Lovrecic L., Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Movement Disorders 2007, 22:1962-1964.
119. Huang H.C., Chang P., Dai X.L., Jiang Z.F. Protective effects of curcumin on amyloid-beta-induced neuronal oxidative damage. Neurochemical Research 2012, 37:1584-1597.
120. Ikehata M., Ueda K., Iwakawa S. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines. Biological & Pharmaceutical Bulletin 2012, 35:301-307.
121. Isham C.R., Tibodeau J.D., Jin W., Xu R., Timm M.M., Bible K.C. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007, 109:2579-2588.
122. Iwamoto F.M., Lamborn K.R., Kuhn J.G., Wen P.Y., Yung W.K., Gilbert M.R., Chang S.M., Lieberman F.S., Prados M.D., Fine H.A. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro-oncology 2011, 13:509-516.
123. Iyer L.M., Abhiman S., Aravind L. Natural history of eukaryotic DNA methylation systems. Progress in Molecular Biology and Translational Science 2011, 101:25-104.
124. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
125. Jones P., Bottomley M.J., Carfi A., Cecchetti O., Ferrigno F., Lo Surdo P., Ontoria J.M., Rowley M., Scarpelli R., Schultz-Fademrecht C., Steinkuhler C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 2008, 18:3456-3461.
126. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 2002, 3:415-428.
127. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
128. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12:206-222.
129. Jurkowski T.P., Jeltsch A. On the evolutionary origin of eukaryotic DNA methyltransferases and Dnmt2. PLoS One 2011, 6:e28104.
130. Kadia T.M., Jabbour E., Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Seminars in Oncology 2011, 38:682-692.
131. Kaminskyy V.O., Surova O.V., Vaculova A., Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011, 32:1450-1458.
132. Karam J.A., Fan J., Stanfield J., Richer E., Benaim E.A., Frenkel E., Antich P., Sagalowsky A.I., Mason R.P., Hsieh J.T. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. International Journal of Cancer 2007, 120:1795-1802.
133. Keating G.M. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2012, 72:1111-1136.
134. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. The Biochemical Journal 2008, 409:581-589.
135. Khan S.B., Maududi T., Barton K., Ayers J., Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. British Journal of Haematology 2004, 125:156-161.
136. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. The Journal of Biological Chemistry 1993, 268:22429-22435.
137. Kikuchi J., Wada T., Shimizu R., Izumi T., Akutsu M., Mitsunaga K., Noborio-Hatano K., Nobuyoshi M., Ozawa K., Kano Y., Furukawa Y. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010, 116:406-417.
138. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., van der Meer R., Nguyen P., Savage J., Owens K.M., et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
139. Kimura S., Kuramoto K., Homan J., Naruoka H., Ego T., Nogawa M., Sugahara S., Naito H. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. Anticancer Research 2012, 32:795-798.
140. Kirschbaum M., Frankel P., Popplewell L., Zain J., Delioukina M., Pullarkat V., Matsuoka D., Pulone B., Rotter A.J., Espinoza-Delgado I., et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology 2011, 29:1198-1203.
141. Kitazono M., Robey R., Zhan Z., Sarlis N.J., Skarulis M.C., Aikou T., Bates S., Fojo T. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. The Journal of Clinical Endocrinology and Metabolism 2001, 86:3430-3435.
142. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J.J., Pandolfi P.P., Nimer S.D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clinical Cancer Research 2008, 14:826-832.
143. Klisovic R.B., Stock W., Cataland S., Klisovic M.I., Liu S., Blum W., Green M., Odenike O., Godley L., Burgt J.V., et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clinical Cancer Research 2008, 14:2444-2449.
144. Knipstein J., Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opinion on Investigational Drugs 2011, 20:1455-1467.
145. Kobayashi T., Hashimoto S., Horie T. Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochemical Pharmacology 1997, 54:819-824.
146. Kozikowski A.P., Chen Y., Gaysin A., Chen B., D'Annibale M.A., Suto C.M., Langley B.C. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. Journal of Medicinal Chemistry 2007, 50:3054-3061.
147. Kramer O.H., Gottlicher M., Heinzel T. Histone deacetylase as a therapeutic target. Trends in Endocrinology and Metabolism 2001, 12:294-300.
148. Kubicek S., O'Sullivan R.J., August E.M., Hickey E.R., Zhang Q., Teodoro M.L., Rea S., Mechtler K., Kowalski J.A., Homon C.A., et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Molecular Cell 2007, 25:473-481.
149. Kuendgen A., Bug G., Ottmann O.G., Haase D., Schanz J., Hildebrandt B., Nachtkamp K., Neukirchen J., Dienst A., Haas R., et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clinical Epigenetics 2011, 2:389-399.
150. Kulis M., Esteller M. DNA methylation and cancer. Advances in Genetics 2010, 70:27-56.
151. Kurd S.K., Smith N., VanVoorhees A., Troxel A.B., Badmaev V., Seykora J.T., Gelfand J.M. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. Journal of the American Academy of Dermatology 2008, 58:625-631.
152. Kwon H.J., Owa T., Hassig C.A., Shimada J., Schreiber S.L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:3356-3361.
153. Lagneaux L., Gillet N., Stamatopoulos B., Delforge A., Dejeneffe M., Massy M., Meuleman N., Kentos A., Martiat P., Willems L., Bron D. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Experimental Hematology 2007, 35:1527-1537.
154. Lai M.T., Yang C.C., Lin T.Y., Tsai F.J., Chen W.C. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urologic Oncology 2008, 26:182-189.
155. Lau O.D., Kundu T.K., Soccio R.E., Ait-Si-Ali S., Khalil E.M., Vassilev A., Wolffe A.P., Nakatani Y., Roeder R.G., Cole P.A. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Molecular Cell 2000, 5:589-595.
156. Lee M.G., Wynder C., Schmidt D.M., McCafferty D.G., Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chemistry & Biology 2006, 13:563-567.
157. Lee W.J., Shim J.Y., Zhu B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Molecular Pharmacology 2005, 68:1018-1030.
158. Leone G., Teofili L., Voso M.T., Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002, 87:1324-1341.
159. Lin L., Liu Y., Li H., Li P.K., Fuchs J., Shibata H., Iwabuchi Y., Lin J. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. British Journal of Cancer 2011, 105:212-220.
160. Liu F., Chen X., Allali-Hassani A., Quinn A.M., Wasney G.A., Dong A., Barsyte D., Kozieradzki I., Senisterra G., Chau I., et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. Journal of Medicinal Chemistry 2009, 52:7950-7953.
161. Liu Q.Y., Chen D.W., Xie L.P., Zhang R.Q., Wang H.Z. Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells. Environmental Toxicology and Pharmacology 2011, 32:423-429.
162. Liu Z., Zhang L., Ding F., Li J., Guo M., Li W., Wang Y., Yu Z., Zhan Q., Wu M., Liu Z. 5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Letters 2005, 230:271-283.
163. Lokk K., Vooder T., Kolde R., Valk K., Vosa U., Roosipuu R., Milani L., Fischer K., Koltsina M., Urgard E., et al. Methylation markers of early-stage non-small cell lung cancer. PLoS One 2012, 7:e39813.
164. Lu Q., Wu A., Richardson B.C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. Journal of Immunology 2005, 174:6212-6219.
165. Lucas D.M., Davis M.E., Parthun M.R., Mone A.P., Kitada S., Cunningham K.D., Flax E.L., Wickham J., Reed J.C., Byrd J.C., Grever M.R. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004, 18:1207-1214.
166. Luchenko V.L., Salcido C.D., Zhang Y., Agama K., Komlodi-Pasztor E., Murphy R.F., Giaccone G., Pommier Y., Bates S.E., Varticovski L. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011, 10:3119-3128.
167. Mabaera R., Greene M.R., Richardson C.A., Conine S.J., Kozul C.D., Lowrey C.H. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood 2008, 111:411-420.
168. Mai A., Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. The International Journal of Biochemistry & Cell Biology 2009, 41:199-213.
169. Mai A., Massa S., Pezzi R., Valente S., Loidl P., Brosch G. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Medicinal Chemistry 2005, 1:245-254.
170. Maiso P., Carvajal-Vergara X., Ocio E.M., Lopez-Perez R., Mateo G., Gutierrez N., Atadja P., Pandiella A., San Miguel J.F. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Research 2006, 66:5781-5789.
171. Marks P.A., Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology 2007, 25:84-90.
172. Marks P.W. Decitabine for acute myeloid leukemia. Expert Review of Anticancer Therapy 2012, 12:299-305.
173. Mazumder A., Vesole D.H., Jagannath S. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. Clinical Lymphoma, Myeloma & Leukemia 2010, 10:149-151.
174. McGovern A.P., Powell B.E., Chevassut T.J. A dynamic multi-compartmental model of DNA methylation with demonstrable predictive value in hematological malignancies. Journal of Theoretical Biology 2012, 310C:14-20.
175. McGuinness D., McGuinness D.H., McCaul J.A., Shiels P.G. Sirtuins, bioageing, and cancer. Journal of Aging Research 2011, 235754.
176. McKinsey T.A., Olson E.N. Cardiac histone acetylation - therapeutic opportunities abound. Trends in Genetics 2004, 20:206-213.
177. Meng X.Y., Zhu S.T., Zhou Q.Z., Li P., Wang Y.J., Zhang S.T. Promoter methylation regulates cigarette smoke-stimulated cyclooxygenase-2 expression in esophageal squamous cell carcinoma. Journal of Digestive Diseases 2012, 13:208-213.
178. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer 2006, 6:38-51.
179. Mirza S., Sharma G., Pandya P., Ralhan R. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Molecular and Cellular Biochemistry 2010, 342:101-109.
180. Modesitt S.C., Sill M., Hoffman J.S., Bender D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2008, 109:182-186.
181. Moffat D., Patel S., Day F., Belfield A., Donald A., Rowlands M., Wibawa J., Brotherton D., Stimson L., Clark V., et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrim idine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. Journal of Medicinal Chemistry 2010, 53:8663-8678.
182. Moradei O., Vaisburg A., Martell R.E. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Current Topics in Medicinal Chemistry 2008, 8:841-858.
183. Mouzaoui S., Rahim I., Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-alpha-induced oxidative stress, colitis and hepatotoxicity in mice. International Immunopharmacology 2012, 12:302-311.
184. Munster P.N., Thurn K.T., Thomas S., Raha P., Lacevic M., Miller A., Melisko M., Ismail-Khan R., Rugo H., Moasser M., Minton S.E. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British Journal of Cancer 2011, 104:1828-1835.
185. Nagaraju G.P., Aliya S., Zafar S.F., Basha R., Diaz R., El-Rayes B.F. The impact of curcumin on breast cancer. Integrative Biology 2012, 4(9):996-1007.
186. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Experimental Cell Research 1998, 241:126-133.
187. Nandakumar V., Vaid M., Katiyar S.K. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 2011, 32:537-544.
188. Newmark H.L., Lupton J.R., Young C.W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Letters 1994, 78:1-5.
189. Niesvizky R., Ely S., Mark T., Aggarwal S., Gabrilove J.L., Wright J.J., Chen-Kiang S., Sparano J.A. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117:336-342.
190. Nightingale K.P., O'Neill L.P., Turner B.M. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Current Opinion in Genetics & Development 2006, 16:125-136.
191. Nolan L., Johnson P.W., Ganesan A., Packham G., Crabb S.J. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. British Journal of Cancer 2008, 99:689-694.
192. Novotny-Diermayr V., Hart S., Goh K.C., Cheong A., Ong L.C., Hentze H., Pasha M.K., Jayaraman R., Ethirajulu K., Wood J.M. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer Journal 2012, 2:e69.
193. Novotny-Diermayr V., Sangthongpitag K., Hu C.Y., Wu X., Sausgruber N., Yeo P., Greicius G., Pettersson S., Liang A.L., Loh Y.K., et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Molecular Cancer Therapeutics 2010, 9:642-652.
194. Oki Y., Kondo Y., Yamamoto K., Ogura M., Kasai M., Kobayashi Y., Watanabe T., Uike N., Ohyashiki K., Okamoto S.I., et al. A phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Science 2012, 103(10):1839-18347.
195. Olindo S., Belrose G., Gillet N., Rodriguez S., Boxus M., Verlaeten O., Asquith B., Bangham C., Signate A., Smadja D., et al. Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood 2011, 118:6306-6309.
196. Olivieri N.F., Saunthararajah Y., Thayalasuthan V., Kwiatkowski J., Ware R.E., Kuypers F.A., Kim H.Y., Trachtenberg F.L., Vichinsky E.P. A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood 2011, 118:2708-2711.
197. Otterson G.A., Hodgson L., Pang H., Vokes E.E. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). Journal of Thoracic Oncology 2010, 5:1644-1648.
198. Patutina O.A., Mironova N.L., Vlassov V.V., Zenkova M.A. New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. Acta Naturae 2009, 1:44-60.
199. Peedicayil J. The role of DNA methylation in the pathogenesis and treatment of cancer. Current Clinical Pharmacology 2012, 7(4):333-340.
200. Peng X., Pentassuglia L., Sawyer D.B. Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?. Circulation Research 2010, 106:1022-1034.
201. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. The Journal of Biological Chemistry 2001, 276:36734-36741.
202. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., Jaffe E.S., Ling A., Turner M., Peer C.J., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
203. Platzbecker U., Schetelig J., Finke J., Trenschel R., Scott B.L., Kobbe G., Schaefer-Eckart K., Bornhauser M., Itzykson R., Germing U., et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biology of Blood and Marrow Transplantation 2012, 18(9):1415-1421.
204. Plitta B., Giel-Pietraszuk M., Markiewicz W.T., Barciszewski J. Cytosine methylation in DNA and its role in cancer therapy. Postepy Biochemii 2011, 57:24-32.
205. Plummer R., Vidal L., Griffin M., Lesley M., de Bono J., Coulthard S., Sludden J., Siu L.L., Chen E.X., Oza A.M., et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clinical Cancer Research 2009, 15:3177-3183.
206. Pontiki E., Hadjipavlou-Litina D. Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives. Medicinal Research Reviews 2012, 32:1-165.
207. Prebet T., Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs 2011, 20:287-295.
208. Prince H.M., Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clinical Cancer Research 2012, 18:3509-3515.
209. Rabizadeh E., Merkin V., Belyaeva I., Shaklai M., Zimra Y. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leukemia Research 2007, 31:1115-1123.
210. Rajendran G., Shanmuganandam K., Bendre A., Muzumdar D., Goel A., Shiras A. Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. Journal of Neuro-oncology 2011, 104:483-494.
211. Rambaldi A., Dellacasa C.M., Finazzi G., Carobbio A., Ferrari M.L., Guglielmelli P., Gattoni E., Salmoiraghi S., Finazzi M.C., Di Tollo S., et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology 2010, 150:446-455.
212. Rapin J.R., Wiernsperger N. Possible links between intestinal permeability and food processing: a potential therapeutic niche for glutamine. Clinics (Sao Paulo) 2010, 65:635-643.
213. Rasheed W.K., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs 2007, 16:659-678.
214. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell 2007, 26:731-743.
215. Razak A.R., Hotte S.J., Siu L.L., Chen E.X., Hirte H.W., Powers J., Walsh W., Stayner L.A., Laughlin A., Novotny-Diermayr V., et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. British Journal of Cancer 2011, 104:756-762.
216. Ree A.H., Dueland S., Folkvord S., Hole K.H., Seierstad T., Johansen M., Abrahamsen T.W., Flatmark K. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. The Lancet Oncology 2010, 11:459-464.
217. Reid T., Valone F., Lipera W., Irwin D., Paroly W., Natale R., Sreedharan S., Keer H., Lum B., Scappaticci F., Bhatnagar A. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004, 45:381-386.
218. Ren J., Singh B.N., Huang Q., Li Z., Gao Y., Mishra P., Hwa Y.L., Li J., Dowdy S.C., Jiang S.W. DNA hypermethylation as a chemotherapy target. Cellular Signalling 2011, 23:1082-1093.
219. Rennolds J., Malireddy S., Hassan F., Tridandapani S., Parinandi N., Boyaka P.N., Cormet-Boyaka E. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. Biochemical and Biophysical Research Communications 2012, 417:256-261.
220. Rice J.C., Allis C.D. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Current Opinion in Cell Biology 2001, 13:263-273.
221. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., Sun L., Ricker J., Rizvi S., Oerth C., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & Lymphoma 2008, 49:502-507.
222. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:3003-3007.
223. Ritchie E.K. Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Clinical Interventions in Aging 2012, 7:165-173.
224. Robertson K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20:3139-3155.
225. Robertson K.D., Wolffe A.P. DNA methylation in health and disease. Nature Reviews Genetics 2000, 1:11-19.
226. Rosato R., Hock S., Dent P., Dai Y., Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leukemia Research 2012, 36:491-498.
227. Rosato R.R., Maggio S.C., Almenara J.A., Payne S.G., Atadja P., Spiegel S., Dent P., Grant S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology 2006, 69:216-225.
228. Rose C., Fournier M., Nibourel O., Herbaux C., Charpentier A., Renneville A., Pissard S., Badens C., Preudhomme C. Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy. Leukemia Research 2011, 35:e203-205.
229. Ruana B.F., Lua X.Q., Songa J., Zhu H.L. Derivatives of resveratrol: potential agents in prevention and treatment of cardiovascular disease. Current Medicinal Chemistry 2012, 19(24):4175-4183.
230. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry 2005, 93:1087-1098.
231. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4592-4597.
232. Sato A., Asano T., Horiguchi A., Ito K., Sumitomo M., Asano T. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. Urology 2010, 76:764.e7-764.e13.
233. Sato N., Ohta T., Kitagawa H., Kayahara M., Ninomiya I., Fushida S., Fujimura T., Nishimura G., Shimizu K., Miwa K. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. International Journal of Oncology 2004, 24:679-685.
234. Saunders L.R., Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007, 26:5489-5504.
235. Saunthararajah Y., Hillery C.A., Lavelle D., Molokie R., Dorn L., Bressler L., Gavazova S., Chen Y.H., Hoffman R., DeSimone J. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003, 102:3865-3870.
236. Schaefer M., Lyko F. Solving the Dnmt2 enigma. Chromosoma 2010, 119:35-40.
237. Schaefer M., Pollex T., Hanna K., Tuorto F., Meusburger M., Helm M., Lyko F. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes & Development 2010, 24:1590-1595.
238. Schirrmacher E., Beck C., Brueckner B., Schmitges F., Siedlecki P., Bartenstein P., Lyko F., Schirrmacher R. Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjugate Chemistry 2006, 17:261-266.
239. Schmidt D.M., McCafferty D.G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46:4408-4416.
240. Schneider B.J., Kalemkerian G.P., Bradley D., Smith D.C., Egorin M.J., Daignault S., Dunn R., Hussain M. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Investigational New Drugs 2012, 30:249-257.
241. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., Hancox A., Hong J.A., Chen G.A., Kruchin E., et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clinical Cancer Research 2008, 14:188-198.
242. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., Hancox A., Hong J.A., Chen G.A., Pishchik V., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clinical Cancer Research 2006, 12:5777-5785.
243. Scuto A., Kirschbaum M., Kowolik C., Kretzner L., Juhasz A., Atadja P., Pullarkat V., Bhatia R., Forman S., Yen Y., Jove R. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008, 111:5093-5100.
244. Shabbeer S., Williams S.A., Simons B.W., Herman J.G., Carducci M.A. Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence. Cancer Prevention Research (Philadelphia, PA) 2012, 5:229-239.
245. Shang D., Liu Y., Matsui Y., Ito N., Nishiyama H., Kamoto T., Ogawa O. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology 2008, 71:1220-1225.
246. Shankar S., Srivastava R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Advances in Experimental Medicine and Biology 2008, 615:261-298.
247. Shao W., Growney J.D., Feng Y., O'Connor G., Pu M., Zhu W., Yao Y.M., Kwon P., Fawell S., Atadja P. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. International Journal of Cancer 2010, 127:2199-2208.
248. Shi Y., Desponts C., Do J.T., Hahm H.S., Scholer H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
249. Shi Y.K., Li Z.H., Han X.Q., Yi J.H., Wang Z.H., Hou J.L., Feng C.R., Fang Q.H., Wang H.H., Zhang P.F., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemotherapy and Pharmacology 2010, 66:1131-1140.
250. Shukla V., Vaissiere T., Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutation Research 2008, 637:1-15.
251. Siegel D., Hussein M., Belani C., Robert F., Galanis E., Richon V.M., Garcia-Vargas J., Sanz-Rodriguez C., Rizvi S. Vorinostat in solid and hematologic malignancies. Journal of Hematology & Oncology 2009, 2:31.
252. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation Research 2008, 647:21-29.
253. Singh N., Duenas-Gonzalez A., Lyko F., Medina-Franco J.L. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 2009, 4:792-799.
254. Siu L.L., Pili R., Duran I., Messersmith W.A., Chen E.X., Sullivan R., MacLean M., King S., Brown S., Reid G.K., et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of Clinical Oncology 2008, 26:1940-1947.
255. Smith B.C., Denu J.M. Chemical mechanisms of histone lysine and arginine modifications. Biochimica et Biophysica Acta 2009, 1789:45-57.
256. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12:1325-1334.
257. Son D.S., Wilson A.J., Parl A.K., Khabele D. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biology & Therapy 2010, 9:928-935.
258. Song S.H., Han S.W., Bang Y.J. Epigenetic-based therapies in cancer: progress to date. Drugs 2011, 71:2391-2403.
259. Sorm F., Piskala A., Cihak A., Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964, 20:202-203.
260. Souto J.A., Benedetti R., Otto K., Miceli M., Alvarez R., Altucci L., de Lera A.R. New anacardic acid-inspired benzamides: histone lysine acetyltransferase activators. ChemMedChem 2010, 5:1530-1540.
261. Souto J.A., Conte M., Alvarez R., Nebbioso A., Carafa V., Altucci L., de Lera A.R. Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. ChemMedChem 2008, 3:1435-1442.
262. Spannhoff A., Hauser A.T., Heinke R., Sippl W., Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 2009, 4:1568-1582.
263. Spannhoff A., Sippl W., Jung M. Cancer treatment of the future: inhibitors of histone methyltransferases. The International Journal of Biochemistry & Cell Biology 2009, 41:4-11.
264. Stadler W.M., Margolin K., Ferber S., McCulloch W., Thompson J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical Genitourinary Cancer 2006, 5:57-60.
265. Stamatopoulos B., Meuleman N., De Bruyn C., Mineur P., Martiat P., Bron D., Lagneaux L. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009, 23:2281-2289.
266. Stathis A., Hotte S.J., Chen E.X., Hirte H.W., Oza A.M., Moretto P., Webster S., Laughlin A., Stayner L.A., McGill S., et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clinical Cancer Research 2011, 17:1582-1590.
267. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiology and Molecular Biology Reviews 2000, 64:435-459.
268. Stewart D.J., Donehower R.C., Eisenhauer E.A., Wainman N., Shah A.K., Bonfils C., MacLeod A.R., Besterman J.M., Reid G.K. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Annals of Oncology 2003, 14:766-774.
269. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
270. Stuhmer T., Arts J., Chatterjee M., Borawski J., Wolff A., King P., Einsele H., Leo E., Bargou R.C. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. British Journal of Haematology 2010, 149:529-536.
271. Stunkel W., Campbell R.M. Sirtuin 1 (SIRT1): the misunderstood HDAC. Journal of Biomolecular Screening 2011, 16:1153-1169.
272. Suzuki T., Tanaka R., Hamada S., Nakagawa H., Miyata N. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorganic & Medicinal Chemistry Letters 2010, 20:1124-1127.
273. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annual Review of Pharmacology and Toxicology 2009, 49:243-263.
274. Talero E., Avila-Rom J., Motilva V. Chemoprevention with phytonutrients and microalgae products in chronic inflammation and colon cancer. Current Pharmaceutical Design 2012, 18(26):3939-3965.
275. Tarasenko N., Nudelman A., Tarasenko I., Entin-Meer M., Hass-Kogan D., Inbal A., Rephaeli A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clinical & Experimental Metastasis 2008, 25:703-716.
276. Tate C.R., Rhodes L.V., Segar H.C., Driver J.L., Pounder F.N., Burow M.E., Collins-Burow B.M. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Research 2012, 14:R79.
277. Tibodeau J.D., Benson L.M., Isham C.R., Owen W.G., Bible K.C. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxidants & Redox Signaling 2009, 11:1097-1106.
278. Tinari N., De Tursi M., Grassadonia A., Zilli M., Stuppia L., Iacobelli S., Natoli C. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Current Cancer Drug Targets 2012, 12:439-452.
279. Tong W.G., Wei Y., Stevenson W., Kuang S.Q., Fang Z., Zhang M., Arts J., Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leukemia Research 2010, 34:221-228.
280. Tseng C.K., Marquez V.E., Fuller R.W., Goldstein B.M., Haines D.R., McPherson H., Parsons J.L., Shannon W.M., Arnett G., Hollingshead M., et al. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosyl homocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. Journal of Medicinal Chemistry 1989, 32:1442-1446.
281. Vaquero A. The conserved role of sirtuins in chromatin regulation. The International Journal of Developmental Biology 2009, 53:303-322.
282. Veeck J., Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. Journal of Mammary Gland Biology and Neoplasia 2010, 15:5-17.
283. Veeraraghavan J., Natarajan M., Lagisetty P., Awasthi V., Herman T.S., Aravindan N. Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells. Pancreas 2011, 40:1107-1119.
284. Villa R., De Santis F., Gutierrez A., Minucci S., Pelicci P.G., Di Croce L. Epigenetic gene silencing in acute promyelocytic leukemia. Biochemical Pharmacology 2004, 68:1247-1254.
285. Warrell R.P., He L.Z., Richon V., Calleja E., Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute 1998, 90:1621-1625.
286. Watanabe Y., Maekawa M. Methylation of DNA in cancer. Advances in Clinical Chemistry 2010, 52:145-167.
287. Westphal C.H., Dipp M.A., Guarente L. A therapeutic role for sirtuins in diseases of aging?. Trends in Biochemical Sciences 2007, 32:555-560.
288. Whitehead R.P., Rankin C., Hoff P.M., Gold P.J., Billingsley K.G., Chapman R.A., Wong L., Ward J.H., Abbruzzese J.L., Blanke C.D. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2009, 27:469-475.
289. Wild L., Flanagan J.M. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochimica et Biophysica Acta 2010, 1806:50-57.
290. Winquist E., Knox J., Ayoub J.P., Wood L., Wainman N., Reid G.K., Pearce L., Shah A., Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Investigational New Drugs 2006, 24:159-167.
291. Wu F., Hu C.H. Reversal effect of 5-Aza-dc on cisplatin-resistance in human NSCLC cells in vitro. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 2011, 33:349-353.
292. Xu F., Mao C., Ding Y., Rui C., Wu L., Shi A., Zhang H., Zhang L., Xu Z. Molecular and enzymatic profiles of mammalian DNA methyltransferases: structures and targets for drugs. Current Medicinal Chemistry 2010, 17:4052-4071.
293. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
294. Yamamoto H., Schoonjans K., Auwerx J. Sirtuin functions in health and disease. Molecular Endocrinology 2007, 21:1745-1755.
295. Yan L., Nass S.J., Smith D., Nelson W.G., Herman J.G., Davidson N.E. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biology & Therapy 2003, 2:552-556.
296. Yang D., Torres C.M., Bardhan K., Zimmerman M., McGaha T.L., Liu K. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. Journal of Immunology 2012, 188:4441-4449.
297. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Research 2004, 32:959-976.
298. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. The Journal of Biological Chemistry 1990, 265:17174-17179.
299. Younes A., Oki Y., Bociek R.G., Kuruvilla J., Fanale M., Neelapu S., Copeland A., Buglio D., Galal A., Besterman J., et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. The Lancet Oncology 2011, 12:1222-1228.
300. Zhou Q., Atadja P., Davidson N.E. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biology & Therapy 2007, 6:64-69.